UA73152C2 - Condensed azepins as agonists of vasopressin - Google Patents

Condensed azepins as agonists of vasopressin Download PDF

Info

Publication number: UA73152C2
Authority: UA; Ukraine
Prior art keywords: pharmaceutically acceptable; acceptable salt; compound according; methyl; ylcarbonyl
Prior art date: 2000-01-05

Application number

UA2002075517A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-05

Filing date

2001-04-01

Publication date

2005-06-15

2001-04-01 Application filed filed Critical

2005-06-15 Publication of UA73152C2 publication Critical patent/UA73152C2/uk

Links

239000000556 agonist Substances 0.000 title abstract description 8
108010004977 Vasopressins Proteins 0.000 title description 16
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title description 16
102000002852 Vasopressins Human genes 0.000 title description 15
229960003726 vasopressin Drugs 0.000 title description 15
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title description 14
150000001875 compounds Chemical class 0.000 claims abstract description 64
239000000203 mixture Substances 0.000 claims abstract description 29
125000000217 alkyl group Chemical group 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
201000010064 diabetes insipidus Diseases 0.000 claims abstract description 8
208000008967 Enuresis Diseases 0.000 claims abstract description 6
208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 claims abstract description 6
201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 claims abstract description 6
206010029446 nocturia Diseases 0.000 claims abstract description 6
208000005346 nocturnal enuresis Diseases 0.000 claims abstract description 6
125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
208000028235 central diabetes insipidus Diseases 0.000 claims abstract description 5
125000002619 bicyclic group Chemical group 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims description 26
238000000034 method Methods 0.000 claims description 19
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
208000032843 Hemorrhage Diseases 0.000 claims description 5
230000000740 bleeding effect Effects 0.000 claims description 5
208000004880 Polyuria Diseases 0.000 claims description 3
206010046543 Urinary incontinence Diseases 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
208000034158 bleeding Diseases 0.000 claims description 3
230000003111 delayed effect Effects 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 2
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 2
230000033228 biological regulation Effects 0.000 claims description 2
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims 2
235000019256 formaldehyde Nutrition 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
229910052717 sulfur Inorganic materials 0.000 abstract description 10
229910052801 chlorine Inorganic materials 0.000 abstract description 8
230000002686 anti-diuretic effect Effects 0.000 abstract description 6
229910052760 oxygen Inorganic materials 0.000 abstract description 6
229910052731 fluorine Inorganic materials 0.000 abstract description 5
229910052794 bromium Inorganic materials 0.000 abstract description 4
102000004136 Vasopressin Receptors Human genes 0.000 abstract description 3
108090000643 Vasopressin Receptors Proteins 0.000 abstract description 3
229940124538 antidiuretic agent Drugs 0.000 abstract description 3
150000001538 azepines Chemical class 0.000 abstract description 3
229940083335 Vasopressin agonist Drugs 0.000 abstract description 2
239000003805 procoagulant Substances 0.000 abstract description 2
239000012634 fragment Substances 0.000 description 26
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 11
239000001257 hydrogen Substances 0.000 description 11
229910052739 hydrogen Inorganic materials 0.000 description 11
239000000243 solution Substances 0.000 description 11
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 10
229960004281 desmopressin Drugs 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
210000002700 urine Anatomy 0.000 description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
150000001412 amines Chemical class 0.000 description 8
-1 hydroxymethylene Chemical group 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
239000007787 solid Substances 0.000 description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
206010021639 Incontinence Diseases 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
125000004434 sulfur atom Chemical group 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
238000003818 flash chromatography Methods 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
150000003141 primary amines Chemical class 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
LTRYUAZFLOGRLJ-UHFFFAOYSA-N 4-cyano-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1C#N LTRYUAZFLOGRLJ-UHFFFAOYSA-N 0.000 description 3
102100026735 Coagulation factor VIII Human genes 0.000 description 3
201000003542 Factor VIII deficiency Diseases 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
208000009292 Hemophilia A Diseases 0.000 description 3
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 3
208000027276 Von Willebrand disease Diseases 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
239000013058 crude material Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000013504 emergency use authorization Methods 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
125000004430 oxygen atom Chemical group O* 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
108010047303 von Willebrand Factor Proteins 0.000 description 3
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 3
102100036537 von Willebrand factor Human genes 0.000 description 3
229960001134 von willebrand factor Drugs 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000012267 brine Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000003480 eluent Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000010410 layer Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000007726 management method Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
XTZCVWDSGCVDFI-UHFFFAOYSA-N methyl 4-(bromomethyl)-3-chlorobenzoate Chemical compound COC(=O)C1=CC=C(CBr)C(Cl)=C1 XTZCVWDSGCVDFI-UHFFFAOYSA-N 0.000 description 2
150000002829 nitrogen Chemical class 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
229940127264 non-peptide agonist Drugs 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
150000003235 pyrrolidines Chemical class 0.000 description 2
239000000018 receptor agonist Substances 0.000 description 2
229940044601 receptor agonist Drugs 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
150000003512 tertiary amines Chemical class 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
WQADWIOXOXRPLN-AZXPZELESA-N 1,3-dithiane Chemical group C1CS[13CH2]SC1 WQADWIOXOXRPLN-AZXPZELESA-N 0.000 description 1
IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
XDYHDIYQYUGFBR-UHFFFAOYSA-N 1h-1-benzazepine-2-carbonitrile Chemical compound N1C(C#N)=CC=CC2=CC=CC=C21 XDYHDIYQYUGFBR-UHFFFAOYSA-N 0.000 description 1
AJUMGSLQADLWKL-UHFFFAOYSA-N 1h-azepine;hydrochloride Chemical compound Cl.N1C=CC=CC=C1 AJUMGSLQADLWKL-UHFFFAOYSA-N 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
ZUNRWCIMDCYBIQ-UHFFFAOYSA-N 3-chloro-4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=C1Cl ZUNRWCIMDCYBIQ-UHFFFAOYSA-N 0.000 description 1
LPEBMDFRIKYFCF-UHFFFAOYSA-N 4-bromo-2-methylbenzonitrile Chemical compound CC1=CC(Br)=CC=C1C#N LPEBMDFRIKYFCF-UHFFFAOYSA-N 0.000 description 1
NIDKGLRXRBFGEN-UHFFFAOYSA-N 4-cyano-2-methylbenzoic acid Chemical compound CC1=CC(C#N)=CC=C1C(O)=O NIDKGLRXRBFGEN-UHFFFAOYSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010069632 Bladder dysfunction Diseases 0.000 description 1
102000017926 CHRM2 Human genes 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
101150012960 Chrm2 gene Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101710092453 Peptide hormone 2 Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
244000117054 Rungia klossii Species 0.000 description 1
235000002492 Rungia klossii Nutrition 0.000 description 1
206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001559 benzoic acids Chemical class 0.000 description 1
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
230000002950 deficient Effects 0.000 description 1
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000007789 gas Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000027939 micturition Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000007084 physiological dysfunction Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940125422 potassium channel blocker Drugs 0.000 description 1
239000003450 potassium channel blocker Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
208000022170 stress incontinence Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Cephalosporin Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA2002075517A 2000-01-05 2001-04-01 Condensed azepins as agonists of vasopressin UA73152C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0000079.4A GB0000079D0 (en)	2000-01-05	2000-01-05	Novel antidiuretic agents
PCT/GB2001/000023 WO2001049682A1 (en)	2000-01-05	2001-01-04	Condensed azepines as vasopressin agonists

Publications (1)

Publication Number	Publication Date
UA73152C2 true UA73152C2 (en)	2005-06-15

Family

ID=9883168

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002075517A UA73152C2 (en)	2000-01-05	2001-04-01	Condensed azepins as agonists of vasopressin

Country Status (34)

Country	Link
US (3)	US7074781B2 (ru)
EP (1)	EP1248784B1 (ru)
JP (2)	JP3869723B2 (ru)
KR (1)	KR100605466B1 (ru)
CN (1)	CN1183129C (ru)
AR (1)	AR035327A1 (ru)
AT (1)	ATE366730T1 (ru)
AU (1)	AU777538B2 (ru)
BR (1)	BR0107414B1 (ru)
CA (1)	CA2396277C (ru)
CY (1)	CY1108034T1 (ru)
CZ (1)	CZ303444B6 (ru)
DE (1)	DE60129298T2 (ru)
DK (1)	DK1248784T3 (ru)
EE (1)	EE200200367A (ru)
ES (1)	ES2288923T3 (ru)
GB (1)	GB0000079D0 (ru)
HK (1)	HK1046910B (ru)
HR (1)	HRP20020481B1 (ru)
HU (1)	HU229937B1 (ru)
IL (1)	IL149528A0 (ru)
MX (1)	MXPA02006546A (ru)
MY (1)	MY140467A (ru)
NO (1)	NO322571B1 (ru)
NZ (1)	NZ518803A (ru)
PL (1)	PL211341B1 (ru)
PT (1)	PT1248784E (ru)
RU (1)	RU2259367C2 (ru)
SI (1)	SI1248784T1 (ru)
SK (1)	SK287005B6 (ru)
UA (1)	UA73152C2 (ru)
UY (1)	UY26521A1 (ru)
WO (1)	WO2001049682A1 (ru)
ZA (1)	ZA200205180B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138393B2 (en)	1998-07-24	2006-11-21	Wyeth	Biologically active vasopressin agonist metabolites
GB0000079D0 (en) *	2000-01-05	2000-02-23	Ferring Bv	Novel antidiuretic agents
IL151911A0 (en) *	2000-03-27	2003-04-10	Applied Research Systems	Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them
UA74362C2 (ru) *	2000-03-27	2005-12-15	Еплайд Рісьорч Системз Ерс Холдінг Н.В.	Фармацевтически активные производные пирролидина
GB0015601D0 (en)	2000-06-26	2000-08-16	Ferring Bv	Novel antidiuretic agents
GB0115515D0 (en) *	2001-06-25	2001-08-15	Ferring Bv	Oxytocin agonisys
GB0210397D0 (en) *	2002-05-07	2002-06-12	Ferring Bv	Pharmaceutical formulations
BRPI0409718A (pt)	2003-04-28	2006-05-02	Astellas Pharma Inc	derivado de 4,4-difluoro-1,2,3,4-tetraidro-5h-1-benzazepina ou seu sal
DK1530967T3 (da) *	2003-11-13	2006-07-03	Ferring Bv	Blisterpakning og dertil hörende fast dosisform
JP4943858B2 (ja) *	2004-11-17	2012-05-30	キッセイ薬品工業株式会社	芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途
EP1867639A1 (en) *	2005-03-25	2007-12-19	Kissei Pharmaceutical Co., Ltd.	Urea derivative, medicinal composition containing the same, and medicinal use of these
WO2007052517A1 (ja) *	2005-10-31	2007-05-10	Sumitomo Chemical Company, Limited	ヒドロキシ－２－ピロリジンカルボキシアミド化合物の製法
JP5220611B2 (ja) *	2006-09-25	2013-06-26	キッセイ薬品工業株式会社	１，４−ベンゾジアゼピン誘導体、それを含有する医薬組成物およびそれらの医薬用途
CN101686983A (zh) *	2007-05-10	2010-03-31	Amr科技公司	芳基和杂芳基取代的四氢苯并-1,4-二氮杂䓬及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途
WO2009021007A1 (en)	2007-08-06	2009-02-12	Serenity Pharmaceuticals Corporation	Methods and devices for desmopressin drug delivery
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
PT2712622T (pt) *	2008-05-21	2016-10-13	Ferring Bv	Desmopressina orodispersível para aumentar o período inicial de sono tranquilo
GB201005623D0 (en)	2010-04-01	2010-05-19	Vantia Ltd	New polymorph
GB201105537D0 (en) *	2011-03-31	2011-05-18	Vantia Ltd	New process
WO2020154581A1 (en)	2019-01-24	2020-07-30	Assia Chemical Industries Ltd	Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3960886A (en) *	1968-07-03	1976-06-01	Sterling Drug Inc.	Substituted N-arylanilines
CA1047490A (en) *	1973-04-18	1979-01-30	Friedrich Karrer	Ethers
CH599752A5 (ru) *	1973-04-18	1978-05-31	Ciba Geigy Ag
DE2355454A1 (de)	1973-11-07	1976-10-07	Paul Geisslinger	Lochmaschine
EP0186817B1 (en)	1984-12-10	1989-08-02	Nissan Chemical Industries Ltd.	3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
EP0450097B1 (en)	1989-10-20	1996-04-24	Otsuka Pharmaceutical Co., Ltd.	Benzoheterocyclic compounds
US5753677A (en) *	1989-10-20	1998-05-19	Otsuka Pharmaceutical Co., Ltd.	Benzoheterocyclic compounds
CA2066104C (en)	1991-04-19	2003-05-27	Hidenori Ogawa	Benzazepine derivatives as vasopressin antagonists
JPH05320135A (ja) *	1992-05-19	1993-12-03	Yamanouchi Pharmaceut Co Ltd	テトラヒドロベンズアゼピン誘導体
EP0612319A1 (en) *	1992-08-20	1994-08-31	Otsuka Pharmaceutical Co., Ltd.	Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
TW270927B (ru) *	1992-10-16	1996-02-21	Otsuka Pharma Co Ltd
AU5533894A (en)	1992-11-25	1994-06-22	Yamanouchi Pharmaceutical Co., Ltd.	Benzanilide derivative
AU6219994A (en)	1993-03-11	1994-09-26	Yamanouchi Pharmaceutical Co., Ltd.	Compound with vasopressin antagonism
GB9307527D0 (en)	1993-04-13	1993-06-02	Fujisawa Pharmaceutical Co	New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5760031A (en) *	1993-07-29	1998-06-02	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
US5516774A (en)	1993-07-29	1996-05-14	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5968930A (en) *	1993-07-29	1999-10-19	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5843952A (en) *	1993-07-29	1998-12-01	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
FI1215U1 (fi) *	1993-12-03	1994-02-21	Valmet Paper Machinery Inc	Anlaeggning i samband med styrningen av en vira
DE69514191T2 (de) *	1994-05-06	2000-08-17	Koninklijke Philips Electronics N.V., Eindhoven	Mikrowellenübertragungssystem
KR100433375B1 (ko)	1994-06-15	2005-09-23	오쓰까 세이야꾸 가부시키가이샤	벤조헤테로고리유도체
JP2926335B2 (ja) *	1997-06-13	1999-07-28	大塚製薬株式会社	医薬組成物
EP1000062B1 (en) *	1997-07-30	2004-09-22	Wyeth	Tricyclic vasopressin agonists
NZ502448A (en) *	1997-07-30	2002-12-20	Wyeth Corp	Tricyclic vasopressin agonists and medicaments containing these compounds
AU763460B2 (en) *	1998-10-09	2003-07-24	Janssen Pharmaceutica N.V.	4,5-dihydro-isoxazole derivatives and their pharmaceutical use
GB2355454A (en) *	1999-10-20	2001-04-25	Ferring Bv	Antidiuretic agents
GB0000079D0 (en) *	2000-01-05	2000-02-23	Ferring Bv	Novel antidiuretic agents
GB0015601D0 (en) *	2000-06-26	2000-08-16	Ferring Bv	Novel antidiuretic agents
DE10033337A1 (de)	2000-07-08	2002-01-17	Boehringer Ingelheim Pharma	Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0120051D0 (en)	2001-08-16	2001-10-10	Ferring Bv	Oxytocin agonists
GB0224557D0 (en)	2002-10-22	2002-11-27	Glaxo Group Ltd	Novel compounds
EP1449844A1 (en)	2003-02-14	2004-08-25	Ferring B.V.	benzamide derivatives as oxytocin agonists and vasopressin antagonists
EP1627876A1 (en) *	2004-08-20	2006-02-22	Ferring B.V.	Heterocyclic condensed compounds useful as antidiuretic agents
US7341963B2 (en) *	2005-05-17	2008-03-11	Milliken & Company	Non-woven material with barrier skin

2000
- 2000-01-05 GB GBGB0000079.4A patent/GB0000079D0/en not_active Ceased
2001
- 2001-01-04 AU AU23846/01A patent/AU777538B2/en not_active Ceased
- 2001-01-04 DE DE60129298T patent/DE60129298T2/de not_active Expired - Lifetime
- 2001-01-04 KR KR1020027006382A patent/KR100605466B1/ko active IP Right Grant
- 2001-01-04 US US10/130,749 patent/US7074781B2/en not_active Expired - Lifetime
- 2001-01-04 CZ CZ20022305A patent/CZ303444B6/cs not_active IP Right Cessation
- 2001-01-04 CN CNB018031323A patent/CN1183129C/zh not_active Expired - Fee Related
- 2001-01-04 EE EEP200200367A patent/EE200200367A/xx unknown
- 2001-01-04 NZ NZ518803A patent/NZ518803A/xx not_active IP Right Cessation
- 2001-01-04 PT PT01900169T patent/PT1248784E/pt unknown
- 2001-01-04 EP EP01900169A patent/EP1248784B1/en not_active Expired - Lifetime
- 2001-01-04 WO PCT/GB2001/000023 patent/WO2001049682A1/en active IP Right Grant
- 2001-01-04 BR BRPI0107414-8A patent/BR0107414B1/pt not_active IP Right Cessation
- 2001-01-04 RU RU2002120798/04A patent/RU2259367C2/ru not_active IP Right Cessation
- 2001-01-04 ES ES01900169T patent/ES2288923T3/es not_active Expired - Lifetime
- 2001-01-04 SI SI200130766T patent/SI1248784T1/sl unknown
- 2001-01-04 UY UY26521A patent/UY26521A1/es not_active IP Right Cessation
- 2001-01-04 HU HU0203917A patent/HU229937B1/hu not_active IP Right Cessation
- 2001-01-04 IL IL14952801A patent/IL149528A0/xx active IP Right Grant
- 2001-01-04 JP JP2001550222A patent/JP3869723B2/ja not_active Expired - Fee Related
- 2001-01-04 AT AT01900169T patent/ATE366730T1/de active
- 2001-01-04 MY MYPI20010027A patent/MY140467A/en unknown
- 2001-01-04 SK SK911-2002A patent/SK287005B6/sk not_active IP Right Cessation
- 2001-01-04 DK DK01900169T patent/DK1248784T3/da active
- 2001-01-04 PL PL355808A patent/PL211341B1/pl unknown
- 2001-01-04 MX MXPA02006546A patent/MXPA02006546A/es active IP Right Grant
- 2001-01-04 AR ARP010100035A patent/AR035327A1/es active IP Right Grant
- 2001-01-04 CA CA2396277A patent/CA2396277C/en not_active Expired - Lifetime
- 2001-04-01 UA UA2002075517A patent/UA73152C2/uk unknown
2002
- 2002-05-31 HR HR20020481A patent/HRP20020481B1/xx not_active IP Right Cessation
- 2002-06-27 NO NO20023137A patent/NO322571B1/no not_active IP Right Cessation
- 2002-06-27 ZA ZA200205180A patent/ZA200205180B/en unknown
- 2002-11-26 HK HK02108525.5A patent/HK1046910B/zh not_active IP Right Cessation
2005
- 2005-12-20 JP JP2005366100A patent/JP3813629B2/ja not_active Expired - Fee Related
2006
- 2006-03-09 US US11/370,861 patent/US7560454B2/en not_active Expired - Fee Related
2007
- 2007-10-04 CY CY20071101261T patent/CY1108034T1/el unknown
2008
- 2008-06-23 US US12/213,651 patent/US20080261951A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2396277C (en)	2012-03-20
SI1248784T1 (sl)	2007-12-31
SK9112002A3 (en)	2003-01-09
JP2006137767A (ja)	2006-06-01
CZ303444B6 (cs)	2012-09-19
US20080261951A1 (en)	2008-10-23
RU2259367C2 (ru)	2005-08-27
ES2288923T3 (es)	2008-02-01
KR100605466B1 (ko)	2006-07-28
UY26521A1 (es)	2001-03-16
GB0000079D0 (en)	2000-02-23
NO20023137L (no)	2002-06-27
WO2001049682A1 (en)	2001-07-12
CN1392875A (zh)	2003-01-22
US20060154916A1 (en)	2006-07-13
JP2003519228A (ja)	2003-06-17
CN1183129C (zh)	2005-01-05
EP1248784A1 (en)	2002-10-16
IL149528A0 (en)	2002-11-10
PT1248784E (pt)	2007-10-02
HUP0203917A3 (en)	2004-07-28
NZ518803A (en)	2003-03-28
KR20020063191A (ko)	2002-08-01
MXPA02006546A (es)	2002-12-09
BR0107414A (pt)	2002-10-08
CA2396277A1 (en)	2001-07-12
EE200200367A (et)	2003-12-15
HRP20020481B1 (en)	2009-03-31
BR0107414B1 (pt)	2014-09-16
DK1248784T3 (da)	2007-10-29
US7074781B2 (en)	2006-07-11
PL211341B1 (pl)	2012-05-31
HK1046910A1 (en)	2003-01-30
US20030087892A1 (en)	2003-05-08
MY140467A (en)	2009-12-31
US7560454B2 (en)	2009-07-14
ZA200205180B (en)	2004-02-05
EP1248784B1 (en)	2007-07-11
NO20023137D0 (no)	2002-06-27
HU229937B1 (hu)	2015-01-28
AU777538B2 (en)	2004-10-21
DE60129298D1 (de)	2007-08-23
JP3813629B2 (ja)	2006-08-23
HUP0203917A2 (hu)	2003-03-28
PL355808A1 (en)	2004-05-17
CZ20022305A3 (cs)	2002-10-16
NO322571B1 (no)	2006-10-30
AR035327A1 (es)	2004-05-12
AU2384601A (en)	2001-07-16
RU2002120798A (ru)	2004-01-10
SK287005B6 (sk)	2009-09-07
DE60129298T2 (de)	2008-01-03
HK1046910B (zh)	2007-08-31
CY1108034T1 (el)	2013-09-04
HRP20020481A2 (en)	2004-08-31
ATE366730T1 (de)	2007-08-15
JP3869723B2 (ja)	2007-01-17

Publication	Publication Date	Title
UA73152C2 (en)	2005-06-15	Condensed azepins as agonists of vasopressin
EP1627876A1 (en)	2006-02-22	Heterocyclic condensed compounds useful as antidiuretic agents
US6664249B1 (en)	2003-12-16	Bicyclic vasopressin agonists
UA126099C2 (uk)	2022-08-10	Сполука, яка виявляє інгібувальну активність відносно ентеропептидази
DD239210A5 (de)	1986-09-17	Verfahren zur herstellung neuer 5-amino-4-hydroxyvaleryl-derivate
UA77209C2 (en)	2006-11-15	Benzothiazepine and benzothiadiazepine derivatives inhibiting bile acid ileal transfer, their use for treatment of hyperlipidaemia, method for their manufacture (variants), pharmaceutical composition (variants)